- Serán BioScience has increased its CGMP clinical manufacturing capacity by 130% at its Bend, Oregon facility.
- The expansion includes eight new process manufacturing suites, enhancing the company’s capability for late-stage clinical trial supplies.
Serán BioScience, LLC, a drug development partner, has completed a significant expansion of its manufacturing facility in Bend, Oregon. The increase in capacity comes with the addition of eight new state-of-the-art process suites, bringing the total number of suites from six to 14. This expansion enhances the company’s CGMP clinical manufacturing capacity by approximately 130%.
The newly added suites will provide flexible capacity for late-stage clinical trials of small-molecule medicines. This development aligns with Serán’s commitment to its ‘Right-From-the-Start™’ approach, which offers comprehensive solutions including bioavailability enhancement, modified release tablets, and engineered particles for inhalation.
Dan Smithey, Ph.D., President, CEO, and Co-founder of Serán BioScience, stated, “We are excited to announce the expansion at the site, where we can now provide mid- and large-scale manufacturing unit operations to support our clients’ journey from first-in-human studies through to pivotal trials and registration.”
The expanded facility remains within Serán’s existing campus, which includes 10 buildings and a total of 90,000 square feet of space. The new suites are equipped with advanced technologies for a broad range of oral solid and inhaled dosage forms, including nano milling, micronization, and tablet coating. The workforce at the site now exceeds 190.
